Welcome to our dedicated page for First Wave BioPharma SEC filings (Ticker: FWBI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to SEC filings historically associated with First Wave BioPharma, Inc. (FWBI), the company that later changed its name to Entero Therapeutics, Inc. and now trades on the Nasdaq Capital Market under the symbol ENTO. These filings offer detailed information on the company’s GI-focused biopharmaceutical activities, capital structure, and corporate actions.
Registration statements on Form S-1 and S-1/A describe Entero Therapeutics’ business overview as a clinical-stage developer of targeted, non-systemic therapies for gastrointestinal diseases. They outline the evolution of the pipeline, including the focus on the biologic adrulipase for exocrine pancreatic insufficiency and the historical programs for latiglutenase, capeserod, and niclosamide. These documents also explain the company’s status as a smaller reporting company and provide risk factor and capitalization details.
Current reports on Form 8-K capture material events such as the May 2024 corporate name change from First Wave BioPharma, Inc. to Entero Therapeutics, Inc., the merger with ImmunogenX, Inc., financing agreements involving pre-funded warrants and common warrants, board and executive changes, and the approval and implementation of a 1-for-3 reverse stock split. Other 8-K filings discuss Nasdaq listing compliance matters and extensions related to stockholders’ equity and annual meeting requirements.
Later S-1 and S-1/A filings, along with resale registration statements, provide additional detail on offerings of common stock and pre-funded warrants, the use of proceeds, and the terms of securities purchase agreements and registration rights agreements.
On Stock Titan, these FWBI-linked filings are updated from EDGAR and can be paired with AI-powered summaries that highlight key points from lengthy documents, such as how the company describes its GI disease focus, the status of adrulipase and other programs, and the implications of capital markets transactions. Users can also review information related to stock splits and listing status as disclosed in the company’s SEC reports.